PROF Valuation

Profound Medical Corp

Add to Watchlist

Advanced Chart

4.470

-0.06(-1.325%)1D

Overview
Forecast
Valuation
Earnings

PROF Relative Valuation

PROF's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PROF is overvalued; if below, it's undervalued.

Historical Valuation

Profound Medical Corp (PROF) is now in the Undervalued zone, suggesting that its current forward PS ratio of 4.89 is considered Undervalued compared with the five-year average of -8.92. The fair price of Profound Medical Corp (PROF) is between 7.16 to 22.16 according to relative valuation methord. Compared to the current price of 4.47 USD , Profound Medical Corp is Undervalued By 37.55%.

Relative Value

Fair Zone

7.16-22.16

Current Price：4.47

37.55%

Undervalued

-3.03

Trailing

Forward

-2.59

EV/EBITDA

Profound Medical Corp. (PROF) has a current EV/EBITDA of -2.59. The 5-year average EV/EBITDA is -8.26. The thresholds are as follows: Strongly Undervalued below -18.30, Undervalued between -18.30 and -13.28, Fairly Valued between -3.24 and -13.28, Overvalued between -3.24 and 1.78, and Strongly Overvalued above 1.78. The current Forward EV/EBITDA of -2.59 falls within the Overvalued range.

-2.22

EV/EBIT

Profound Medical Corp. (PROF) has a current EV/EBIT of -2.22. The 5-year average EV/EBIT is -6.71. The thresholds are as follows: Strongly Undervalued below -13.97, Undervalued between -13.97 and -10.34, Fairly Valued between -3.07 and -10.34, Overvalued between -3.07 and 0.56, and Strongly Overvalued above 0.56. The current Forward EV/EBIT of -2.22 falls within the Overvalued range.

4.87

Profound Medical Corp. (PROF) has a current PS of 4.87. The 5-year average PS is 18.83. The thresholds are as follows: Strongly Undervalued below -1.67, Undervalued between -1.67 and 8.58, Fairly Valued between 29.07 and 8.58, Overvalued between 29.07 and 39.32, and Strongly Overvalued above 39.32. The current Forward PS of 4.87 falls within the Undervalued range.

0.00

P/OCF

Profound Medical Corp. (PROF) has a current P/OCF of 0.00. The 5-year average P/OCF is -14.57. The thresholds are as follows: Strongly Undervalued below -52.85, Undervalued between -52.85 and -33.71, Fairly Valued between 4.57 and -33.71, Overvalued between 4.57 and 23.70, and Strongly Overvalued above 23.70. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Profound Medical Corp. (PROF) has a current P/FCF of 0.00. The 5-year average P/FCF is -21.41. The thresholds are as follows: Strongly Undervalued below -119.41, Undervalued between -119.41 and -70.41, Fairly Valued between 27.58 and -70.41, Overvalued between 27.58 and 76.58, and Strongly Overvalued above 76.58. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Profound Medical Corp (PROF) has a current Price-to-Book (P/B) ratio of 3.47. Compared to its 3-year average P/B ratio of 4.52 , the current P/B ratio is approximately -23.26% higher. Relative to its 5-year average P/B ratio of 4.07, the current P/B ratio is about -14.84% higher. Profound Medical Corp (PROF) has a Forward Free Cash Flow (FCF) yield of approximately -25.56%. Compared to its 3-year average FCF yield of -13.42%, the current FCF yield is approximately 90.37% lower. Relative to its 5-year average FCF yield of -11.54% , the current FCF yield is about 121.44% lower.

3.47

P/B

Median3y

4.52

Median5y

4.07

-25.64

FCF Yield

Median3y

-13.42

Median5y

-11.54

Competitors Valuation Multiple

The average P/S ratio for PROF's competitors is 4.17, providing a benchmark for relative valuation. Profound Medical Corp Corp (PROF) exhibits a P/S ratio of 4.89, which is 17.11% above the industry average. Given its robust revenue growth of -0.99%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

PROF.O

Profound Medical Corp

Utah Medical Products Inc

KORU Medical Systems Inc

Performance Decomposition

Market capitalization of PROF increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of PROF in the past 1 year is driven by Unknown.